{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:58:44Z","timestamp":1791244724309,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Vaccine effectiveness studies have rarely implemented strategies to reduce the healthy vaccinee bias arising from differences in health care\u2013seeking behavior between vaccinated and unvaccinated individuals. Although previous observational studies suggest that influenza vaccination is associated with a reduced risk of SARS-CoV-2\u2013associated outcomes, the healthy vaccinee bias may have led to overestimating the vaccination effect.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the association between influenza vaccination and SARS-CoV-2\u2013associated outcomes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study was conducted over 2 consecutive influenza vaccination campaigns (2019-2020 and 2020-2021), owing to the substantial COVID-19 burden and the greater validity of influenza vaccination data in the studied age group. The study population included community-dwelling adults aged 66 years or older in Ontario, Canada.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Influenza vaccination for a given season.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The outcomes of interest included SARS-CoV-2 infection, SARS-CoV-2\u2013associated hospitalization, SARS-CoV-2\u2013associated death, and a composite of SARS-CoV-2\u2013associated hospitalization or death. Cox proportional hazards models were used to measure the association between influenza vaccination and SARS-CoV-2\u2013associated outcomes, censoring individuals who moved into long-term care, received COVID-19 vaccines, or died before the observation period end date. Primary care periodic health examinations (PHEs) were explored as a negative tracer exposure (ie, no association expected with SARS-CoV-2 outcomes) and as an effect modifier of the association between influenza vaccination and SARS-CoV-2 outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 2\u202f922\u202f449 individuals aged 66 years or older (54.2% female) living in Ontario, 2 279 805 were included in the study. Among these, 1 234 647 (54.2%) were female and 1 045 158 (45.8%) were male; their mean (SD) age was 75.08 (7.21) years. Those who had received influenza vaccination exhibited a lower incidence of SARS-CoV-2 infection than unvaccinated individuals for the 2019-2020 cohort (adjusted hazards ratio [aHR],\u20090.78; 95% CI, 0.73-0.84) and the 2020-2021 cohort (aHR, 0.76; 95% CI, 0.74-0.78). This association was also observed for SARS-CoV-2\u2013associated hospitalization or death (2019-2020: aHR, 0.83; 95% CI, 0.74-0.92; 2020-2021: aHR, 0.66; 95% CI, 0.63-0.70). Similarly, undergoing a PHE was also associated with a lower incidence of SARS-CoV-2 infection (aHR,\u20090.85; 95% CI, 0.78-0.91) and SARS-CoV-2\u2013associated hospitalization or death (aHR,\u20090.80; 95% CI, 0.70-0.90), and modified the association between influenza vaccination and SARS-CoV-2 infection for vaccinated individuals who underwent PHE (aHR,\u20090.62; 95% CI, 0.52-0.74) and for vaccinated individuals who did not undergo PHE (aHR,<\/jats:sub>\u20090.81; 95% CI, 0.76-0.87), and also SARS-CoV-2\u2013associated hospitalization or death in vaccinated individuals who underwent PHE (aHR,\u20090.66; 95% CI, 0.49-0.88) and vaccinated individuals who did not undergo PHE (aHR,\u20090.85, 95% CI, 0.76-0.95).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this cohort study suggest that undergoing a PHE may at least partially modify the association between influenza vaccination and SARS-CoV-2\u2013associated outcomes in individuals aged 66 years or older, providing evidence of the healthy vaccinee bias that may affect vaccine effectiveness studies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.33730","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:35:28Z","timestamp":1664379328000},"page":"e2233730","source":"Crossref","is-referenced-by-count":36,"title":["Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older"],"prefix":"10.1001","volume":"5","author":[{"given":"Seyed M.","family":"Hosseini-Moghaddam","sequence":"first","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"He","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Calzavara","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Campitelli","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Public Health Ontario, Toronto, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"25","key":"zoi220962r1","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates.","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi220962r2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/vaccines9050529","article-title":"The association between influenza vaccination and COVID-19 and its outcomes: a systematic review and meta-analysis of observational studies.","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"zoi220962r3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/bmjebm-2020-111549","article-title":"Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil.","volume":"26","author":"Fink","year":"2020","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"zoi220962r4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jmv.v93.1","article-title":"Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy.","volume":"93","author":"Mar\u00edn-Hern\u00e1ndez","year":"2021","journal-title":"J Med Virol"},{"key":"zoi220962r5","article-title":"Influenza vaccination and COVID19 mortality in the USA.","author":"Zanettini","journal-title":"Vaccines"},{"key":"zoi220962r6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.710647","article-title":"Influenza viruses: innate immunity and mRNA vaccines.","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"zoi220962r7","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/s41598-021-83641-y","article-title":"Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.","volume":"11","author":"Pawlowski","year":"2021","journal-title":"Sci Rep"},{"key":"zoi220962r8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clicom.2021.10.001","article-title":"The \u201coriginal antigenic sin\u201d and its relevance for SARS-CoV-2 (COVID-19) vaccination.","volume":"1","author":"Rijkers","year":"2021","journal-title":"Clin Immunol Commun"},{"issue":"6","key":"zoi220962r9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ajic.2021.02.012","article-title":"Impact of the influenza vaccine on COVID-19 infection rates and severity.","volume":"49","author":"Conlon","year":"2021","journal-title":"Am J Infect Control"},{"issue":"6","key":"zoi220962r10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1080\/21645515.2020.1833577","article-title":"Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19.","volume":"17","author":"Mosaddeghi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"zoi220962r11","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic.","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"zoi220962r12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12879-015-1154-y","article-title":"Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review.","volume":"15","author":"Remschmidt","year":"2015","journal-title":"BMC Infect Dis"},{"key":"zoi220962r13","doi-asserted-by":"publisher","first-page":"n567","DOI":"10.1136\/bmj.n567","article-title":"COVID-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study.","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"zoi220962r14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jclinepi.2008.06.014","article-title":"New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors.","volume":"62","author":"Nelson","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"zoi220962r15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/cid\/cit404","article-title":"Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season.","volume":"57","author":"Kwong","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi220962r17","doi-asserted-by":"publisher","first-page":"11025","DOI":"10.1038\/s41598-021-90068-y","article-title":"Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States.","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"issue":"14","key":"zoi220962r19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.vaccine.2019.02.036","article-title":"Bias of influenza vaccine effectiveness estimates from test-negative studies conducted during an influenza pandemic.","volume":"37","author":"Ainslie","year":"2019","journal-title":"Vaccine"},{"issue":"10","key":"zoi220962r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009928","article-title":"Induction of trained immunity by influenza vaccination\u2014impact on COVID-19.","volume":"17","author":"Debisarun","year":"2021","journal-title":"PLoS Pathog"},{"key":"zoi220962r21","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.3389\/fimmu.2018.02936","article-title":"Trained immunity\u2013based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations.","volume":"9","author":"S\u00e1nchez-Ram\u00f3n","year":"2018","journal-title":"Front Immunol"},{"key":"zoi220962r22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fmicb.2018.00083","article-title":"Non-specific effect of vaccines: immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine.","volume":"9","author":"Lee","year":"2018","journal-title":"Front Microbiol"},{"issue":"3","key":"zoi220962r23","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1542\/peds.2006-2836","article-title":"Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.","volume":"120","author":"Piedra","year":"2007","journal-title":"Pediatrics"},{"issue":"2","key":"zoi220962r24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiu079","article-title":"Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.","volume":"210","author":"Cao","year":"2014","journal-title":"J Infect Dis"},{"issue":"8270","key":"zoi220962r25","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0140-6736(82)91466-0","article-title":"Interference between outbreaks of respiratory syncytial virus and influenza virus infection.","volume":"1","author":"Anestad","year":"1982","journal-title":"Lancet"},{"issue":"3","key":"zoi220962r26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s15007-018-1580-4","article-title":"Respiratory virus\u2013induced heterologous immunity: part of the problem or part of the solution?","volume":"27","author":"Pusch","year":"2018","journal-title":"Allergo J"},{"issue":"2","key":"zoi220962r27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ije\/dyi275","article-title":"Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors.","volume":"35","author":"Jackson","year":"2006","journal-title":"Int J Epidemiol"},{"issue":"9502","key":"zoi220962r28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(05)67760-4","article-title":"Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.","volume":"366","author":"Granger","year":"2005","journal-title":"Lancet"},{"issue":"10269","key":"zoi220962r29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"zoi220962r30","doi-asserted-by":"publisher","first-page":"n1943","DOI":"10.1136\/bmj.n1943","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: test negative design study.","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"zoi220962r31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings.","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi220962r32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA COVID-19 vaccine among U.S. health care personnel.","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi220962r33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.15585\/mmwr.mm7020e2","article-title":"Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 accines among health care personnel\u201433 U.S. sites, January-March 2021.","volume":"70","author":"Pilishvili","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"zoi220962r34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna vaccines gainst COVID-19 among hospitalized adults aged =65 years\u2014United States, January-March 2021.","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"zoi220962r35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014eight U.S. locations, December 2020-March 2021.","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"zoi220962r36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.15585\/mmwr.mm7011e3","article-title":"Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks\u2014Connecticut, December 2020-February 2021.","volume":"70","author":"Britton","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"zoi220962r37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2188\/jea.JE20180177","article-title":"Commentary: test-negative design reduces confounding by healthcare-seeking attitude in case-control studies.","volume":"29","author":"Ozasa","year":"2019","journal-title":"J Epidemiol"},{"issue":"5","key":"zoi220962r38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/kww064","article-title":"Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness.","volume":"184","author":"Sullivan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi220962r39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ypmed.2015.02.008","article-title":"Association of influenza vaccine uptake with health, access to health care, and medical mistreatment among adults from low-income neighborhoods in New Haven, CT: a classification tree analysis.","volume":"74","author":"Gilstad-Hayden","year":"2015","journal-title":"Prev Med"},{"issue":"30","key":"zoi220962r40","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1016\/j.vaccine.2005.03.008","article-title":"Prevalence and predictors of influenza vaccination among frail, community-living elderly patients: an international observational study.","volume":"23","author":"Landi","year":"2005","journal-title":"Vaccine"},{"issue":"27","key":"zoi220962r41","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1016\/j.vaccine.2004.12.031","article-title":"Factors influencing influenza vaccination uptake in an elderly, community-based sample.","volume":"23","author":"Burns","year":"2005","journal-title":"Vaccine"},{"key":"zoi220962r42","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160009","author":"Schwartz","year":"2016","journal-title":"CMAJ Open"},{"key":"zoi220962r16","unstructured":"Public Health Ontario. Coronavirus disease 2019 (COVID-19)\u2014PCR. 2021. Accessed November 6, 2020. https:\/\/www.publichealthontario.ca\/en\/laboratory-services\/test-information-index\/covid-19"},{"key":"zoi220962r18","doi-asserted-by":"crossref","unstructured":"Debisarun? PA, Struycken? P, Dom\u00ednguez-Andr\u00e9s? J, . The effect of influenza vaccination on trained immunity: impact on COVID-19.? medRxiv. Preprint posted online October 16, 2020. doi:10.1101\/2020.10.14.20212498?","DOI":"10.1101\/2020.10.14.20212498"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796809\/hosseinimoghaddam_2022_oi_220962_1663774076.26056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:35:35Z","timestamp":1664379335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.33730","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}